Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433. doi:10.1001/jama.294.4.433
   PubMed Web of Science ®Google Scholar
• Parker CC, James ND, Brawley CD, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 2022;19(6):e1003998. doi:10.1371/journal.pmed.1003998
   PubMed Web of Science ®Google Scholar
• Bossi A, Foulon S, Maldonado X, et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design. JCO. 2023;41(17_suppl):LBA5000–LBA5000. doi:10.1200/JCO.2023.41.17_suppl.LBA5000
   Web of Science ®Google Scholar
• Liu M, Yang J, Xu B, Zhang X. Tumor metastasis: mechanistic insights and therapeutic interventions. MedComm (2020). 2021;2(4):587–617. doi:10.1002/mco2.100
   PubMedGoogle Scholar
• Paget S. The distribution of secondary growths in cancer of the breast. The Lancet. 1889;133(3421):571–573. doi:10.1016/S0140-6736(00)49915-0
   Google Scholar
• Chu GCY, Chung LWK, Gururajan M, et al. Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics. Asian J Urol. 2019;6(1):65–81. doi:10.1016/j.ajur.2018.11.003
   PubMed Web of Science ®Google Scholar
• Odero-Marah V, Hawsawi O, Henderson V, Sweeney J. Epithelial-Mesenchymal Transition (EMT) and prostate cancer. Adv Exp Med Biol. 2018;1095:101–110. doi:10.1007/978-3-319-95693-0_6
   PubMed Web of Science ®Google Scholar
• Goel S, Bhatia V, Biswas T, Ateeq B. Epigenetic reprogramming during prostate cancer progression: a perspective from development. Semin Cancer Biol. 2022;83:136–151. doi:10.1016/j.semcancer.2021.01.009
   PubMed Web of Science ®Google Scholar
• López J, Añazco-Guenkova AM, Monteagudo-García Ó, Blanco S. Epigenetic and epitranscriptomic control in prostate cancer. Genes (Basel). 2022;13(2):378. doi:10.3390/genes13020378
   PubMed Web of Science ®Google Scholar
• Chaves LP, Melo CM, Saggioro FP, Dos Reis RB, Squire JA. Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics. Genes (Basel). 2021;12(12):1900. doi:10.3390/genes12121900
   PubMed Web of Science ®Google Scholar
• Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15(2):117–134. doi:10.1007/s10911-010-9178-9
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science. 2023;379(6632):eaaw3835. doi:10.1126/science.aaw3835
   PubMed Web of Science ®Google Scholar
• Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013;19(11):1438–1449. doi:10.1038/nm.3336
   PubMed Web of Science ®Google Scholar
• Zhang S, Shen T, Zeng Y. Epigenetic modifications in prostate cancer metastasis and microenvironment. Cancers. 2023;15(8):2243. doi:10.3390/cancers15082243
   PubMed Web of Science ®Google Scholar
• Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28(10):1057–1068. doi:10.1038/nbt.1685
   PubMed Web of Science ®Google Scholar
• Skvortsova K, Stirzaker C, Taberlay P. The DNA methylation landscape in cancer. Blewitt M, ed. Essays Biochem. 2019;63(6):797–811. doi:10.1042/EBC20190037
   PubMed Web of Science ®Google Scholar
• Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science. 1999;286(5439):481–486. doi:10.1126/science.286.5439.481
   PubMed Web of Science ®Google Scholar
• Sjöström M, Zhao SG, Levy S, et al. The 5-hydroxymethylcytosine landscape of prostate cancer. Cancer Res. 2022;82(21):3888–3902. doi:10.1158/0008-5472.CAN-22-1123
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624–629. doi:10.1038/nature01075
   PubMed Web of Science ®Google Scholar
• Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437(7057):436–439. doi:10.1038/nature04020
   PubMed Web of Science ®Google Scholar
• Gaughan L, Stockley J, Wang N, et al. Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res. 2011;39(4):1266–1279. doi:10.1093/nar/gkq861
   PubMed Web of Science ®Google Scholar
• Ezponda T, Popovic R, Shah MY, et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial–mesenchymal transition and invasive properties of prostate cancer. Oncogene. 2013;32(23):2882–2890. doi:10.1038/onc.2012.297
   PubMed Web of Science ®Google Scholar
• Whitmore WF. Natural history and staging of prostate cancer. Urol Clin North Am. 1984;11(2):205–220. doi:10.1016/S0094-0143(21)00182-8
   PubMed Web of Science ®Google Scholar
• Akoto T, Saini S. Role of exosomes in prostate cancer metastasis. Int J Mol Sci. 2021;22(7):3528. doi:10.3390/ijms22073528
   PubMed Web of Science ®Google Scholar
• Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol. 2011;29(27):3659–3668. doi:10.1200/JCO.2011.35.1916
   PubMed Web of Science ®Google Scholar
• Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228. doi:10.1016/j.cell.2015.05.001
   PubMed Web of Science ®Google Scholar
• Hieronymus H, Sawyers CL. Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat Genet. 2012;44(6):613–614. doi:10.1038/ng.2301
   PubMed Web of Science ®Google Scholar
• Mateo J, Seed G, Bertan C, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2020;130(4):1743–1751. doi:10.1172/JCI132031
   PubMed Web of Science ®Google Scholar
• Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298–305. doi:10.1038/nm.4045
   PubMed Web of Science ®Google Scholar
• Shah RB, Shore KT, Yoon J, Mendrinos S, McKenney JK, Tian W. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma). Prostate. 2019;79(11):1267–1273. doi:10.1002/pros.23831
   PubMed Web of Science ®Google Scholar
• Armstrong CWD, Maxwell PJ, Ong CW, et al. PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. Oncotarget. 2016;7(7):7885–7898. doi:10.18632/oncotarget.6955
   PubMedGoogle Scholar
• Deplus R, Delliaux C, Marchand N, et al. TMPRSS2-ERG fusion promotes prostate cancer metastases in bone. Oncotarget. 2016;8(7):11827–11840. doi:10.18632/oncotarget.14399
   Google Scholar
• Chiarugi P, Paoli P, Cirri P. Tumor microenvironment and metabolism in prostate cancer. Semin Oncol. 2014;41(2):267–280. doi:10.1053/j.seminoncol.2014.03.004
   PubMed Web of Science ®Google Scholar
• Peinado H, Zhang H, Matei IR, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17(5):302–317. doi:10.1038/nrc.2017.6
   PubMed Web of Science ®Google Scholar
• Levesque C, Nelson PS. Cellular constituents of the prostate stroma: key contributors to prostate cancer progression and therapy resistance. Cold Spring Harb Perspect Med. 2018;8(8):a030510. doi:10.1101/cshperspect.a030510
   PubMed Web of Science ®Google Scholar
• Bonollo F, Thalmann GN, Kruithof-de Julio M, Karkampouna S. The role of cancer-associated fibroblasts in prostate cancer tumorigenesis. Cancers. 2020;12(7):1887. doi:10.3390/cancers12071887
   PubMed Web of Science ®Google Scholar
• Thalmann GN, Rhee H, Sikes RA, et al. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP cells. Eur Urol. 2010;58(1):162–172. doi:10.1016/j.eururo.2009.08.026
   PubMed Web of Science ®Google Scholar
• Kang J, La Manna F, Bonollo F, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022;530:156–169. doi:10.1016/j.canlet.2022.01.015
   PubMed Web of Science ®Google Scholar
• Zhang Z, Karthaus WR, Lee YS, et al. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell. 2020;38(2):279–296.e9. doi:10.1016/j.ccell.2020.06.005
   PubMed Web of Science ®Google Scholar
• Ottewell PD, Wang N, Meek J, et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer. 2014;21(5):769–781. doi:10.1530/ERC-14-0199
   PubMed Web of Science ®Google Scholar
• Sun Y, Campisi J, Higano C, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18(9):1359–1368. doi:10.1038/nm.2890
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5(1):21–28. doi:10.1038/nrc1528
   PubMed Web of Science ®Google Scholar
• Perez-Stable C, Altman NH, Mehta PP, Deftos LJ, Roos BA. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res. 1997;57(5):900–906.
   PubMed Web of Science ®Google Scholar
• Arriaga JM, Panja S, Alshalalfa M, et al. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nat Cancer. 2020;1(11):1082–1096. doi:10.1038/s43018-020-00125-0
   PubMedGoogle Scholar
• Lunardi A, Ala U, Epping MT, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013;45(7):747–755. doi:10.1038/ng.2650
   PubMed Web of Science ®Google Scholar
• Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731–2738. doi:10.4049/jimmunol.172.5.2731
   PubMed Web of Science ®Google Scholar
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. A pilot study of mobilization and treatment of disseminated tumor cells in men with metastatic prostate cancer. clinicaltrials.gov; 2019. Available from: https://clinicaltrials.gov/study/NCT02478125. Accessed December 31, 2022.
   Google Scholar
• Martine LC, Holzapfel BM, McGovern JA, et al. Engineering a humanized bone organ model in mice to study bone metastases. Nat Protoc. 2017;12(4):639–663. doi:10.1038/nprot.2017.002
   PubMed Web of Science ®Google Scholar
• Bock N, Kryza T, Shokoohmand A, et al. In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer. Sci Adv. 2021;7(27):eabg2564. doi:10.1126/sciadv.abg2564
   PubMed Web of Science ®Google Scholar
• McGovern JA, Bock N, Shafiee A, et al. A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells. Commun Biol. 2021;4(1):1–14. doi:10.1038/s42003-021-02527-x
   PubMed Web of Science ®Google Scholar
• Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int J Mol Sci. 2021;22(20):11088. doi:10.3390/ijms222011088
   PubMed Web of Science ®Google Scholar
• Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):4507. doi:10.3390/ijms21124507
   PubMed Web of Science ®Google Scholar
• Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci. 2007;104(18):7564–7569. doi:10.1073/pnas.0702507104
   PubMed Web of Science ®Google Scholar
• Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15(4):222–234. doi:10.1038/nrurol.2018.9
   PubMed Web of Science ®Google Scholar
• Blanco-Aparicio C, Renner O, Leal JFM, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis. 2007;28(7):1379–1386. doi:10.1093/carcin/bgm052
   PubMed Web of Science ®Google Scholar
• Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy. Mol Cancer. 2018;17(1):37. doi:10.1186/s12943-018-0803-3
   PubMedGoogle Scholar
• Choudhury AD. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications. Prostate. 2022;82(Suppl 1):S60–S72. doi:10.1002/pros.24372
   PubMedGoogle Scholar
• Cham J, Venkateswaran AR, Bhangoo M. Targeting the PI3K-AKT-mTOR pathway in castration resistant prostate cancer: a review article. Clin Genitourin Cancer. 2021;19(6):563.e1–563.e7. doi:10.1016/j.clgc.2021.07.014
   PubMed Web of Science ®Google Scholar
• de Bono JS, De Giorgi U, Rodrigues DN, et al. Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN Loss. Clin Cancer Res. 2019;25(3):928–936. doi:10.1158/1078-0432.CCR-18-0981
   PubMed Web of Science ®Google Scholar
• Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus Abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2021;398(10295):131–142. doi:10.1016/S0140-6736(21)00580-8
   PubMed Web of Science ®Google Scholar
• Crabb SJ, Griffiths G, Dunkley D, et al. Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial. Eur Urol. 2022;82(5):512–515. doi:10.1016/j.eururo.2022.05.019
   PubMed Web of Science ®Google Scholar
• Fizazi K, George DJ, De Santis M, et al. A phase III trial of capivasertib and Abiraterone versus placebo and Abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281). JCO. 2021;39(6_suppl):TPS178–TPS178. doi:10.1200/JCO.2021.39.6_suppl.TPS178
   Web of Science ®Google Scholar
• Herceg Z, Wang ZQ. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res. 2001;477(1):97–110. doi:10.1016/S0027-5107(01)00111-7
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917. doi:10.1038/nature03443
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. doi:10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• De Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. doi:10.1056/NEJMoa1911440
   PubMed Web of Science ®Google Scholar
• Smith MR, Scher HI, Sandhu S, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022;23(3):362–373. doi:10.1016/S1470-2045(21)00757-9
   PubMed Web of Science ®Google Scholar
• Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38(32):3763–3772. doi:10.1200/JCO.20.01035
   PubMed Web of Science ®Google Scholar
• Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719–732. doi:10.1056/NEJMoa2214676
   PubMed Web of Science ®Google Scholar
• Polkinghorn WR, Parker JS, Lee MX, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3(11):1245–1253. doi:10.1158/2159-8290.CD-13-0172
   PubMed Web of Science ®Google Scholar
• Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015;68(2):186–193. doi:10.1016/j.eururo.2014.10.022
   PubMed Web of Science ®Google Scholar
• Chakraborty G, Armenia J, Mazzu YZ, et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin Cancer Res. 2020;26(8):2047–2064. doi:10.1158/1078-0432.CCR-19-1570
   PubMed Web of Science ®Google Scholar
• Schiewer MJ, Goodwin JF, Han S, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2(12):1134–1149. doi:10.1158/2159-8290.CD-12-0120
   PubMed Web of Science ®Google Scholar
• Li L, Karanika S, Yang G, et al. Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10(480):eaam7479. doi:10.1126/scisignal.aam7479
   PubMed Web of Science ®Google Scholar
• Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374. doi:10.1038/s41467-017-00393-y
   PubMedGoogle Scholar
• Hussain M, Daignault-Newton S, Twardowski PW, et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. JCO. 2018;36(10):991–999. doi:10.1200/JCO.2017.75.7310
   PubMed Web of Science ®Google Scholar
• Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011;19(5):664–678. doi:10.1016/j.ccr.2011.04.010
   PubMed Web of Science ®Google Scholar
• Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362ps17–362ps17. doi:10.1126/scitranslmed.aaf9246
   PubMed Web of Science ®Google Scholar
• Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence. 2022;1(9):EVIDoa2200043. doi:10.1056/EVIDoa2200043
   PubMedGoogle Scholar
• Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer | Journal of Clinical Oncology. Available from: 10.1200/JCO.22.01649. Accessed September 3, 2023
   Google Scholar
• Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10398):291–303. doi:10.1016/S0140-6736(23)01055-3
   PubMed Web of Science ®Google Scholar
• Research C for DE and. FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with Abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer. FDA; July 13, 2023. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-lynparza-olaparib-abiraterone-and-prednisone-brca-mutated. Accessed September 3, 2023.
   Google Scholar
• Research C for DE and. FDA approves niraparib and Abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer. FDA; August 11, 2023. Available from: https://cacmap.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca-mutated-metastatic-castration. Accessed September 3, 2023.
   Google Scholar
• Research C for DE and. FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer. FDA; June 20, 2023. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate. Accessed September 3, 2023.
   Google Scholar